Trial · NCT02027311
Etomidate vs. Midazolam for Sedation During ERCP
NCT02027311, Phase 4, Completed, Cheju Halla General Hospital; results first posted 2015-06-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Etomidate vs. Midazolam for Sedation During ERCP. Trials, record NCT02027311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02027311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Etomidate vs. Midazolam for Sedation During ERCP
- NCT number
- NCT02027311
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 63 participants, actual
- Lead sponsor
- Cheju Halla General Hospital
- Conditions
- Choledocholithiasis, Cholangiocarcinoma, Pancreatitis, Pancreatic Cancer
- Interventions
- Etomidate, Midazolam, Meperidine
- First posted
- 2014-01-06
- Last updated
- 2015-06-29
- Results first posted
- 2015-06-29
- Limitations and caveats
1. To standardize proper sedation level we used Ramsay Sedation Scale but this scale could be calculated subjectively.~2. Double blindness was not applied strictly because of quite different pharmacodynamics of two experimental drugs.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Intervention | Throughout the whole ERCP procedure | The frequency of intervention which was defined as any restraint of the patient's head, arms, or legs if they became agitated, or if patient movement was not controlled with verbal instruction from the endoscopist during the whole intraoperative phases. |
| Secondary | Event of Hypoxia | Every 5min in Preoperative, intraoperative phase and 15 min in Recovery phase | Hypoxia defined as peripheral blood oxygen saturation measured by pulse oxymeter \< 90% |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Intervention | Throughout the whole ERCP procedure | Number of intervention | MEAN | |
| SECONDARY | Event of Hypoxia | Every 5min in Preoperative, intraoperative phase and 15 min in Recovery phase | Hypoxia events | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Intervention | Etomidate | 1.9 | Standard Deviation 3.1 | Number of intervention | |
| Number of Intervention | Midazolam | 7.5 | Standard Deviation 6.8 | Number of intervention | |
| Event of Hypoxia | Midazolam | 19 | Hypoxia events | ||
| Event of Hypoxia | Etomidate | 27 | Hypoxia events |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Etomidate | 33 | |
| Overall Study | STARTED | Midazolam | 35 | |
| Overall Study | COMPLETED | Etomidate | 30 | |
| Overall Study | COMPLETED | Midazolam | 33 | |
| Overall Study | NOT COMPLETED | Etomidate | 3 | |
| Overall Study | NOT COMPLETED | Midazolam | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Etomidate | ||
| Total, all-cause mortality | Midazolam | ||
| Total, other adverse events | Etomidate | 0 | 30 |
| Total, other adverse events | Midazolam | 0 | 33 |
| Total, serious adverse events | Etomidate | 0 | 30 |
| Total, serious adverse events | Midazolam | 0 | 33 |
Source ClinicalTrials.gov
Papers26
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Etomidate vs Midazolam: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02027311
GET https://conductscience.org/api/trials/v1/NCT02027311/papers?page=2